Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janssen-Cilag International
J&J will pay about $6.5bn to acquire Momenta and its potential “pipeline in a pathway” with nipocalimab. Analysts expect this deal may lead to further M&A activity in the anti-FcRn space.
Applications to widen the therapeutic indications of up to 20 approved drugs will be decided on this week at the European Medicines Agency.